263 related articles for article (PubMed ID: 20858850)
1. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
Li SP; Taylor NJ; Makris A; Ah-See ML; Beresford MJ; Stirling JJ; d'Arcy JA; Collins DJ; Padhani AR
Radiology; 2010 Dec; 257(3):643-52. PubMed ID: 20858850
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
[TBL] [Abstract][Full Text] [Related]
3. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy.
Li SP; Makris A; Beresford MJ; Taylor NJ; Ah-See ML; Stirling JJ; d'Arcy JA; Collins DJ; Kozarski R; Padhani AR
Radiology; 2011 Jul; 260(1):68-78. PubMed ID: 21502383
[TBL] [Abstract][Full Text] [Related]
4. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
5. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results.
Padhani AR; Hayes C; Assersohn L; Powles T; Makris A; Suckling J; Leach MO; Husband JE
Radiology; 2006 May; 239(2):361-74. PubMed ID: 16543585
[TBL] [Abstract][Full Text] [Related]
6. Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings--preliminary results.
Makkat S; Luypaert R; Stadnik T; Bourgain C; Sourbron S; Dujardin M; De Greve J; De Mey J
Radiology; 2008 Nov; 249(2):471-82. PubMed ID: 18780825
[TBL] [Abstract][Full Text] [Related]
7. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings.
Woodhams R; Kakita S; Hata H; Iwabuchi K; Kuranami M; Gautam S; Hatabu H; Kan S; Mountford C
Radiology; 2010 Feb; 254(2):357-66. PubMed ID: 20093508
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation.
Yi A; Cho N; Im SA; Chang JM; Kim SJ; Moon HG; Han W; Park IA; Noh DY; Moon WK
Radiology; 2013 Sep; 268(3):662-72. PubMed ID: 23592770
[TBL] [Abstract][Full Text] [Related]
10. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Chow LW; Tung SY; Ng TY; Im SA; Lee MH; Yip AY; Toi M; Glück S
Expert Opin Investig Drugs; 2013 Mar; 22(3):299-307. PubMed ID: 23394482
[TBL] [Abstract][Full Text] [Related]
11. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging.
Hoeks CM; Hambrock T; Yakar D; Hulsbergen-van de Kaa CA; Feuth T; Witjes JA; Fütterer JJ; Barentsz JO
Radiology; 2013 Jan; 266(1):207-17. PubMed ID: 23143029
[TBL] [Abstract][Full Text] [Related]
12. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
13. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging enhancement features before and after neoadjuvant chemotherapy in patients with breast cancer: a predictive value for responders.
Kang DK; Kim TH; Han TS; Kim KS; Yim H
J Comput Assist Tomogr; 2013; 37(3):432-9. PubMed ID: 23674017
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.
Thukral A; Thomasson DM; Chow CK; Eulate R; Wedam SB; Gupta SN; Wise BJ; Steinberg SM; Liewehr DJ; Choyke PL; Swain SM
Radiology; 2007 Sep; 244(3):727-35. PubMed ID: 17709827
[TBL] [Abstract][Full Text] [Related]
16. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
17. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
Denis F; Desbiez-Bourcier AV; Chapiron C; Arbion F; Body G; Brunereau L
Eur J Surg Oncol; 2004 Dec; 30(10):1069-76. PubMed ID: 15522553
[TBL] [Abstract][Full Text] [Related]
18. Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.
Stickeler E; Pils D; Klar M; Orlowsk-Volk M; Zur Hausen A; Jäger M; Watermann D; Gitsch G; Zeillinger R; Tempfer CB
Oncol Rep; 2011 Oct; 26(4):1037-45. PubMed ID: 21769435
[TBL] [Abstract][Full Text] [Related]
19. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Pierga JY; Delaloge S; Espié M; Brain E; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Spielmann M; Savignoni A; Marty M
Breast Cancer Res Treat; 2010 Jul; 122(2):429-37. PubMed ID: 20480225
[TBL] [Abstract][Full Text] [Related]
20. Response to neoadjuvant treatment of invasive ductal breast carcinomas including outcome evaluation: MRI analysis by an automatic CAD system in comparison to visual evaluation.
Böttcher J; Renz DM; Zahm DM; Pfeil A; Fallenberg EM; Streitparth F; Maurer MH; Hamm B; Engelken FJ
Acta Oncol; 2014 Jun; 53(6):759-68. PubMed ID: 24299492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]